In this presentation, Demeetra CEO Jack Crawford shares new data from Demeetra’s CleanCut™ CHO platform, including initial results from a next-generation CleanCut variant engineered for improved product performance.

The CleanCut platform uses Cas-CLOVER for high-fidelity knockouts, paired with Harbor-IN for stable, predictable transgene expression. We will share case studies demonstrating sustained titers, specific productivity, and transgene copy number stability beyond 60 generations in bulk pools, data that supports accelerated IND-enabling timelines without the typical uncertainty around clone stability.

Jack also describes how this platform fits into an integrated CLD-to-GMP workflow developed in collaboration with NorthX Biologics. NorthX contributes three decades of GMP manufacturing expertise, and the combined approach is designed so that cell lines engineered on the CleanCut platform move directly into GMP production, without re-engineering validated clones or navigating downstream licensing friction that can stall programs and complicate asset valuations.

The result is a streamlined path from genome editing to clinical and commercial manufacturing, built around speed, continuity, and operational clarity.

Demeetra provides integrated genome engineering platforms, and products, backed by deep technical expertise.

Contact us to learn how our differentiated IP, flexible access models, and internal know-how can support adoption from discovery through bioprocessing and commercial use.

Buy Products
Schedule A Call